Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

NCT05894135 is registered in ClinicalTrials.gov with Bio Genuine (Shanghai) Biotech Co., Ltd. as lead sponsor.

NCT NCT05894135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05894135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
Lead sponsor
Bio Genuine (Shanghai) Biotech Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
July 14, 2023
Completion date
March 31, 2025
Enrollment
540 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis, moderate to severe endometriosis-associated pain